Substance P

Source: Wikipedia, the free encyclopedia.
tachykinin, precursor 1
Chr. 7 q21-q22
Search for
StructuresSwiss-model
DomainsInterPro
Substance P
Identifiers
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard
 100.046.845 Edit this at Wikidata
IUPHAR/BPS
MeSH Substance+P
UNII
  • InChI=
    1S/C63H98N18O13S/c1-37(2)33-45(57(89)74-41(53(68)85)27-32-95-3)73-52(84)36-72-54(86)46(34-38-15-6-4-7-16-38)78-58(90)47(35-39-17-8-5-9-18-39)79-56(88)42(23-25-50(66)82)75-55(87)43(24-26-51(67)83)76-59(91)49-22-14-31-81(49)62(94)44(20-10-11-28-64)77-60(92)48-21-13-30-80(48)61(93)40(65)19-12-29-71-63(69)70/h4-9,15-18,37,40-49H,10-14,19-36,64-65H2,1-3H3,(H2,66,82)(H2,67,83)(H2,68,85)(H,72,86)(H,73,84)(H,74,89)(H,75,87)(H,76,91)(H,77,92)(H,78,90)(H,79,88)(H4,69,70,71)/t40-,41-,42-,43-,44-,45-,46-,47-,48-,49-/m0/s1
     ☒N
    Key: ADNPLDHMAVUMIW-CUZNLEPHSA-N checkY
  • InChI=
    1/C63H98N18O13S/c1-37(2)33-45(57(89)74-41(53(68)85)27-32-95-3)73-52(84)36-72-54(86)46(34-38-15-6-4-7-16-38)78-58(90)47(35-39-17-8-5-9-18-39)79-56(88)42(23-25-50(66)82)75-55(87)43(24-26-51(67)83)76-59(91)49-22-14-31-81(49)62(94)44(20-10-11-28-64)77-60(92)48-21-13-30-80(48)61(914,19-36,64-65H2,1-3H3,(H2,66,82)(H2,67,83)(H2,68,85)(H,72,86)(H,73,84)(H,74,89)(H,75,87)(H,76,91)(H,77,92)(H,78,90)(H,79,88)(H4,69,70,71)/t40-,41-,42-,43-,44-,45-,46-,47-,48-,49-/m0/s1
    Key: ADNPLDHMAVUMIW-CUZNLEPHBU
Properties
C63H98N18O13S
Molar mass 1347.63 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Substance P (SP) is an

preprotachykinin A gene. The deduced amino acid sequence of substance P is as follows:[4]

with an amide group at the C-terminus.[5] Substance P is released from the terminals of specific

sensory nerves. It is found in the brain and spinal cord and is associated with inflammatory processes and pain
.

Discovery

The original discovery of Substance P (SP) was in 1931 by

John H. Gaddum as a tissue extract that caused intestinal contraction in vitro.[6] Its tissue distribution and biologic actions were further investigated over the following decades.[2] The eleven-amino-acid structure of the peptide was determined by Chang, et. al in 1971.[7]

In 1983,

porcine spinal cord and was also found to stimulate intestinal contraction.[8]

Receptor

The

neurokinin 1 receptor (NK1-receptor, NK1R).[9] It belongs to the tachykinin receptor sub-family of GPCRs.[10] Other neurokinin subtypes and neurokinin receptors that interact with SP have been reported as well. Amino acid residues that are responsible for the binding of SP and its antagonists are present in the extracellular loops and transmembrane regions of NK-1. Binding of SP to NK-1R results in internalization by the clathrin-dependent mechanism to the acidified endosomes where the complex disassociates. Subsequently, SP is degraded and NK-1R is re-expressed on the cell surface.[11]

Substance P and the NK1-receptor are widely distributed in the brain and are found in brain regions that are specific to regulating emotion (

cytokines, it has been proposed that cytokines and neurotropic factors can induce NK-1. Also, SP can induce the cytokines that are capable of inducing NK-1 transcription factors.[15]

Function

Overview

Substance P ("P" standing for "Preparation" or "Powder") is a neuropeptide – but only nominally so, as it is ubiquitous. Its receptor – the neurokinin type 1 – is distributed over cytoplasmic membranes of many cell types (neurons, glia, endothelia of capillaries and lymphatics, fibroblasts, stem cells, white blood cells) in many tissues and organs. SP amplifies or excites most cellular processes.[16][17]

Substance P is a key first responder to most noxious/extreme stimuli (stressors), i.e., those with a potential to compromise an organism's biological integrity. SP is thus regarded as an immediate defense, stress, repair, survival system. The molecule, which is rapidly inactivated (or at times further activated by peptidases) is rapidly released – repetitively and chronically, as warranted, in the presence of a stressor. Unique among biological processes, SP release (and expression of its NK1 Receptor (through autocrine, paracrine, and endocrine-like processes)) may not naturally subside in diseases marked by chronic inflammation (including cancer). The SP or its NK1R, as well as similar neuropeptides, appear to be vital targets capable of satisfying many unmet medical needs. The failure of clinical proof of concept studies, designed to confirm various preclinical predictions of efficacy, is currently a source of frustration and confusion among biomedical researchers.

Vasodilation

Substance P is a potent

vasodilator. Substance P-induced vasodilation is dependent on nitric oxide release.[18] Substance P is involved in the axon reflex-mediated vasodilation to local heating and wheal and flare reaction. It has been shown that vasodilation to substance P is dependent on the NK1 receptor located on the endothelium. In contrast to other neuropeptides studied in human skin, substance P-induced vasodilation has been found to decline during continuous infusion. This possibly suggests an internalization of neurokinin-1 (NK1).[19] As is typical with many vasodilators, it also has bronchoconstrictive
properties, administered through the non-adrenergic, non-cholinergic nervous system (branch of the vagal system).

Inflammation

SP initiates expression of almost all known immunological chemical messengers (cytokines).[20][21][22] Also, most of the cytokines, in turn, induce SP and the NK1 receptor.[23][24] SP is particularly excitatory to cell growth and multiplication,[25] via usual,[26] as well as oncogenic drivers.

emesis.[28] Substance P and other sensory neuropeptides can be released from the peripheral terminals of sensory nerve fibers in the skin, muscle, and joints. It is proposed that this release is involved in neurogenic inflammation, which is a local inflammatory response to certain types of infection or injury.[29]

Pain

Preclinical data support the notion that Substance P is an important element in pain perception. The sensory function of substance P is thought to be related to the transmission of pain information into the

glutamate in primary afferents that respond to painful stimulation.[30] Substance P and other sensory neuropeptides can be released from the peripheral terminals of sensory nerve fibers in the skin, muscle, and joints. It is proposed that this release is involved in neurogenic inflammation, which is a local inflammatory response to certain types of infection or injury.[29]
Unfortunately, the reasons why NK1 receptor antagonists have failed as efficacious analgesics in well-conducted clinical proof of concept studies have not yet been persuasively elucidated.

Mood, anxiety, learning

Substance P has been associated with the regulation of

stress,[31] reinforcement,[32] neurogenesis,[33] synaptic growth and dendritic arborisation,[34] respiratory rhythm,[35] neurotoxicity, pain, and nociception.[36] In 2014, it was found that substance P played a role in male fruit fly aggression.[37] Recently, it has been shown that substance P may play a critical role in long-term potentiation of aversive stimuli. [38]

Vomiting

The vomiting center in the medulla, called the area postrema, contains high concentrations of substance P and its receptor, in addition to other neurotransmitters such as choline, histamine, dopamine, serotonin, and endogenous opioids. Their activation stimulates the vomiting reflex. Different emetic pathways exist, and substance P/NK1R appears to be within the final common pathway to regulate vomiting.[39]

Cell growth, proliferation, angiogenesis, and migration

The above processes are part and parcel to tissue integrity and repair. Substance P has been known to stimulate cell growth in normal and cancer cell line cultures,[40] and it was shown that substance P could promote wound healing of non-healing ulcers in humans.[41] SP and its induced cytokines promote multiplication of cells required for repair or replacement, growth of new blood vessels,[42] and "leg-like pods" on cells (including cancer cells) bestowing upon them mobility,[43] and metastasis.[44] It has been suggested that cancer exploits the SP-NK1R to progress and metastasize, and that NK1RAs may be useful in the treatment of several cancer types.[45][46][47][48]

Clinical significance

Quantification in disease

Elevation of serum, plasma, or tissue SP and/or its receptor (NK1R) has been associated with many diseases: sickle cell crisis;[49] inflammatory bowel disease;[50][51] major depression and related disorders;[52][53][54] fibromyalgia;[55] rheumatological;[56] and infections such as HIV/AIDS and respiratory syncytial virus,[57] as well as in cancer.[58][59] When assayed in the human, the observed variability of the SP concentrations are large, and in some cases the assay methodology is questionable.[60] SP concentrations cannot yet be used to diagnose disease clinically or gauge disease severity. It is not yet known whether changes in concentration of SP or density of its receptors is the cause of any given disease, or an effect.

Blockade for diseases with a chronic immunological component

As increasingly documented, the SP-NK1R system induces or modulates many aspects of the immune response, including WBC production and activation, and cytokine expression,[61] Reciprocally, cytokines may induce expression of SP and its NK1R.[62][63] In this sense, for diseases in which a pro-inflammatory component has been identified or strongly suspected, and for which current treatments are absent or in need of improvement, abrogation of the SP-NK1 system continues to receive focus as a treatment strategy. Currently, the only completely developed method available in that regard is antagonism (blockade, inhibition) of the SP preferring receptor, i.e., by drugs known as neurokinin type 1 antagonists (also termed: SP antagonists, or tachykinin antagonists.) One such drug is aprepitant to prevent the nausea and vomiting that accompanies chemotherapy, typically for cancer. With the exception of chemotherapy-induced nausea and vomiting, the patho-physiological basis of many of the disease groups listed below, for which NK1RAs have been studied as a therapeutic intervention, are to varying extents hypothesized to be initiated or advanced by a chronic non-homeostatic inflammatory response.[17][64][65][66]

Dermatological disorders: eczema/psoriasis, chronic pruritus

High levels of

eczema.[67][68]

Infections: HIV-AIDS, measles, RSV, others

The role of SP in HIV-AIDS has been well-documented.[61] Doses of aprepitant greater than those tested to date are required for demonstration of full efficacy. Respiratory syncytial and related viruses appear to upregulate SP receptors, and rat studies suggest that NK1RAs may be useful in treating or limiting long term sequelae from such infections.[69][70]

protozoan that infects the lower gastrointestinal tract of humans. The symptoms of infection are diarrhea, constipation, and abdominal pain.[71][72] This protozoan was found to secrete serotonin[73] as well as substance P and neurotensin.[74]

Inflammatory bowel disease (IBD)/cystitis

Despite strong preclinical rationale,[75] efforts to demonstrate efficacy of SP antagonists in inflammatory disease have been unproductive. A study in women with IBS confirmed that an NK1RAs antagonist was anxiolytic.[76]

Chemotherapy induced nausea and vomiting

Further information: Chemotherapy-induced nausea and vomiting and Aprepitant

In line with its role as a first line defense system, SP is released when toxicants or poisons come into contact with a range of receptors on cellular elements in the

nucleus of the solitary tract upon integrated activity of dopamine, serotonin, opioid, and/or acetylcholine receptor signaling. NK1Rs are stimulated. In turn, a fairly complex reflex is triggered involving cranial nerves responsible for respiration, retroperistalsis, and general autonomic discharge. The actions of aprepitant are said to be entirely central, thus requiring passage of the drug into the central nervous system.[77] However, given that NK1Rs are unprotected by a blood brain barrier in the area postrema just adjacent to neuronal structures in the medulla, and the activity of sendide (the peptide based NK1RA) against cisplatin-induced emesis in the ferret,[78]
it is likely that some peripheral exposure contributes to antiemetic effects, even if through vagal terminals in the clinical setting.

Other findings

Denervation supersensitivity

When the innervation to substance P nerve terminals is lost, post-synaptic cells compensate for the loss of adequate neurotransmitter by increasing the expression of post-synaptic receptors. This, ultimately, leads to a condition known as denervation supersensitivity as the post-synaptic nerves will become hypersensitive to any release of substance P into the synaptic cleft.

Aggression

Tachykinin / Substance P plays an evolutionarily conserved role in inducing aggressive behaviors.[79] In rodents and cats, activation of hypothalamic neurons which release Substance P induces aggressive behaviors (defensive biting and predatory attack).[80][81][82] Similarly, in fruit flies, tachykinin-releasing neurons have been implicated in aggressive behaviors (lunging).[83][84] In this context, male-specific tachykinin neurons control lunging behaviors that can be modulated by the amount of tachykinin release.[85]

References

  1. Meriam-Webster
    . Retrieved 17 November 2022.
  2. ^
    PMID 11378438
    .
  3. PMID 14754378. Archived from the original
    on 2009-08-17. Retrieved 2008-11-01.
  4. OCLC 57368924
    .
  5. S2CID 31252390
    .
  6. PMID 16994201
    .
  7. PMID 5285346
    .
  8. PMID 6194276
    .
  9. PMID 1657150
    .
  10. PMID 7557266
    .
  11. PMID 7545030
    .
  12. S2CID 33205594
    .
  13. S2CID 24350120
    .
  14. S2CID 36225447
    .
  15. PMID 9344694
    .
  16. PMID 15212980
    .
  17. ^
    S2CID 30899555
    .
  18. PMID 1282120
    .
  19. PMID 16123103
    .
  20. S2CID 45933685
    .
  21. S2CID 6114230
    .
  22. PMID 18576810
    .
  23. PMID 1707535
    .
  24. S2CID 84912440
    .
  25. PMID 15319441
    .
  26. PMID 11067916
    .
  27. PMID 23275336
    .
  28. ^ Hesketh PJ (Jul 2001). "Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting". Supportive Care in Cancer. 9 (5): 350–4.
    S2CID 34636170
    .
  29. ^
    PMID 17618972
    .
  30. S2CID 4324247
    .
  31. S2CID 23380355
    .
  32. S2CID 21680843
    .
  33. PMID 17886560
    .
  34. ^ Baloyannis S, Costa V, Deretzi G, Michmizos D. 1999. Intraventricular Administration of Substance P Increases the Dendritic Arborisation and the Synaptic Surfaces of Purkinje Cells in Rat's Cerebellum. International Journal of Neuroscience, 101(1-4):89-107. https://www.tandfonline.com/doi/abs/10.3109/00207450008986495
  35. PMID 8606995
    .
  36. PMID 11137976
    .
  37. ^ Gorman, James, To Study Aggression, a Fight Club for Flies, The New York Times, February 4, 2014, page D5 of the New York edition
  38. PMID 37995189
    .
  39. PMID 11749934
    .
  40. S2CID 45018815
    .
  41. PMID 9230840
    .
  42. PMID 18597700
    .
  43. PMID 21966499
    .
  44. PMID 21226668
    .
  45. PMID 8988040
    .
  46. PMID 20015033
    .
  47. S2CID 34038324
    .
  48. PMID 24412605
    .
  49. PMID 9787150
    .
  50. PMID 2834738
    .
  51. PMID 9326744
    .
  52. PMID 16585438
    .
  53. PMID 22033776
    .
  54. PMID 12056558
    .
  55. S2CID 41455803
    .
  56. PMID 9051855
    .
  57. PMID 11600835
    .
  58. PMID 10954033
    .
  59. PMID 10618428
    .
  60. PMID 16971517
    .
  61. ^
    S2CID 14975995
    .
  62. PMID 9717978
    .
  63. PMID 14654230
    .
  64. PMID 21091716
    .
  65. PMID 17849359
    .
  66. ISBN 978-90-367-3874-3
    .
  67. S2CID 38031193
    .
  68. PMID 11159042
    .
  69. PMID 11254547
    .
  70. PMID 491812
    .
  71. PMID 17070814
    .
  72. PMID 6308760
    .
  73. PMID 2861068
    .
  74. PMID 24382888
    .
  75. PMID 22221140
    .
  76. S2CID 5350781
    .
  77. PMID 19454547
    .
  78. PMID 31824255
    .
  79. S2CID 38166332
    .
  80. PMID 19344710
    .
  81. S2CID 207357396
    .
  82. S2CID 207745183
    .
  83. ISSN 0362-4331
    . Retrieved 2022-03-24.
  84. PMID 24439378
    .

External links
Retrieved from "https://en.wikipedia.org/w/index.php?title=Substance_P&oldid=1214237933"